SEHK:3696Life Sciences
Insilico Medicine Cayman TopCo FY 2025 Loss Deepens To US$352.3 Million Challenging Bullish Narratives
InSilico Medicine Cayman TopCo (SEHK:3696) has opened FY 2025 with first half revenue of US$27.5 million and a basic EPS loss of US$0.25, while trailing twelve month figures show revenue of US$56.2 million alongside a net loss of US$352.3 million and EPS of US$4.48 in the red. Over the recent reported periods, the company has seen revenue shift from US$59.7 million in the first half of FY 2024 to US$26.1 million in the second half and then to US$27.5 million in the first half of FY 2025. Net...